CRISPR injection targets stubborn high cholesterol in first human trial

NCT ID NCT07491172

Recruiting now Disease control Sponsor: CRISPR Therapeutics AG Source: ClinicalTrials.gov ↗

First seen Mar 24, 2026 · Last updated May 02, 2026 · Updated 3 times

Summary

This early-phase study tests a single-dose CRISPR treatment (CTX310) designed to edit a gene that controls fat levels in the blood. It is for adults aged 18 to 75 with severe high cholesterol or triglycerides that do not improve with standard medications. The main goal is to check safety, but researchers will also measure how much fat levels drop. Because participants may still need ongoing medication, this is a disease-control approach, not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site 1
RECRUITING

Adelaide, 5000, Australia
Research Site 10
NOT_YET_RECRUITING

Jacksonville, Florida, 32216, United States
Research Site 11
NOT_YET_RECRUITING

Port Orange, Florida, 32127, United States
Research Site 12
NOT_YET_RECRUITING

Portland, Oregon, 97239, United States
Research Site 13
NOT_YET_RECRUITING

High Point, North Carolina, 27260, United States
Research Site 14
NOT_YET_RECRUITING

Durham, North Carolina, 27710, United States
Research Site 15
NOT_YET_RECRUITING

Brisbane, 4064, Australia
Research Site 16
NOT_YET_RECRUITING

Brisbane, Australia
Research Site 17
NOT_YET_RECRUITING

Orlando, Florida, 32789, United States
Research Site 18
NOT_YET_RECRUITING

Cambridge, United Kingdom
Research Site 2
RECRUITING

Melbourne, 3168, Australia
Research Site 3
RECRUITING

Heidelberg, 3084, Australia
Research Site 4
RECRUITING

Christchurch, 8011, New Zealand
Research Site 5
RECRUITING

Auckland, 2025, New Zealand
Research Site 6
RECRUITING

London, SE1 1YR, United Kingdom
Research Site 7
NOT_YET_RECRUITING

Camperdown, 2050, Australia
Research Site 8
NOT_YET_RECRUITING

London, E1 1BB, United Kingdom
Research Site 9
NOT_YET_RECRUITING

Cleveland, Ohio, 44195, United States

Conditions

Explore the condition pages connected to this study.

CARDIOVASCULAR DYSLIPIDEMIAS HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) HYPERCHOLESTEROLAEMIA HYPERTRIGLYCERIDEMIA LIPID DISORDER LIPID DISORDER METABOLIC DISEASE MIXED HYPERLIPEMIA SEVERE HYPERTRIGLYCERIDEMIA (SHTG)